Alectinib is a next generation orally available, highly selective, ATP-competitive ALK TKI (31–34), that was approved in July 2014 (Japan) and December 2015 (US) to treat relapsed ALK-positive NSCLC as well as patients that were unable to tolerate crizotinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.